Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4-month long-term study

被引:61
作者
Girndt, M [1 ]
Heisel, O [1 ]
Köhler, H [1 ]
机构
[1] Univ Homburg, Dept Med 4, D-66421 Homburg, Germany
关键词
biocompatibility; complement activation; haemodialysis; interleukin-10; monokines;
D O I
10.1093/ndt/14.3.676
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 [基础医学]; 1002 [临床医学]; 100602 [中西医结合临床];
摘要
Background. Contact between blood and dialysis membranes activates mononuclear cells and the complement system. The extent of activation is dependent on the dialyser material used and is considered an index of biocompatibility. Polyamide dialysers consist of a synthetic membrane that, claims high standards of biocompatibility. Haemophan dialysers represent membranes made of modified cellulose that are now broadly used for treatment in Europe and are already considered to be more biocompatible than the cuprophane membranes that were used as reference in most previous studies. Methods. In a cross-over treatment study short-term as well as long-term effects of a polyamide dialyser with respect to monokine induction and complement activation were compared to a haemophan dialyser. Results. Neither haemophan nor polyamide dialysers induced relevant changes in plasma monokine levels. However, in vitro challenge of mononuclear cells with lipopolysaccharide (LPS) unmasked a significantly stronger preactivation for the secretion of proinflammatory monokines during haemophan than polyamide dialysis. Unlike other monokines the production of the regulatory monokine IL-10 was mainly influenced by individual factors and correlated with the patient's immune status rather than the dialyser type used. Enhanced preactivation of monocytes in haemophan compared to polyamide dialysis was paralleled by an increased complement activation. Cellular preactivation and formation of terminal complement complex remained constant over the 4-month treatment period. Conclusions, Haemophan and polyamide dialysers do not induce changes in plasma cytokine levels both during short-term and long-term use. However, they significantly differ in complement activation as well as preactivation of monocytes. Preactivated monocytes are prone to secrete high amounts of proinflammatory cytokines when exposed to a second stimulus like endotoxin. Secretion of the regulatory cytokine IL-IO is not influenced by the dialyser type.
引用
收藏
页码:676 / 682
页数:7
相关论文
共 24 条
[1]
CUPRAMMONIUM MEMBRANES STIMULATE INTERLEUKIN-1 RELEASE AND ARACHIDONIC-ACID METABOLISM IN MONOCYTES IN THE ABSENCE OF COMPLEMENT [J].
BETZ, M ;
HAENSCH, GM ;
RAUTERBERG, EW ;
BOMMER, J ;
RITZ, E .
KIDNEY INTERNATIONAL, 1988, 34 (01) :67-73
[2]
CUPROPHANE BUT NOT SYNTHETIC MEMBRANE INDUCES INCREASES IN SERUM TUMOR-NECROSIS-FACTOR-ALPHA LEVELS DURING HEMODIALYSIS [J].
CANIVET, E ;
LAVAUD, S ;
WONG, T ;
GUENOUNOU, M ;
WILLEMIN, JC ;
POTRON, G ;
CHANARD, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 23 (01) :41-46
[3]
SERUM INTERLEUKIN-6 IN LONG-TERM HEMODIALYZED PATIENTS [J].
CAVAILLON, JM ;
POIGNET, JL ;
FITTING, C ;
DELONS, S .
NEPHRON, 1992, 60 (03) :307-313
[4]
CHOLLETMARTIN S, 1991, CLIN EXP IMMUNOL, V83, P329
[5]
INCREASED LIPID-PEROXIDATION IN PATIENTS ON MAINTENANCE HEMODIALYSIS [J].
DASGUPTA, A ;
HUSSAIN, S ;
AHMAD, S .
NEPHRON, 1992, 60 (01) :56-59
[6]
DAUGIRDAS JT, 1994, HDB DIALYSIS
[7]
FLUID PHASE GENERATION OF TERMINAL COMPLEMENT COMPLEX AS A NOVEL INDEX OF BIOINCOMPATIBILITY [J].
DEPPISCH, R ;
SCHMITT, V ;
BOMMER, J ;
HANSCH, GM ;
RITZ, E ;
RAUTERBERG, EW .
KIDNEY INTERNATIONAL, 1990, 37 (02) :696-706
[8]
EFFECT OF DIALYSIS MEMBRANE AND PATIENTS AGE ON SIGNS OF DIALYSIS-RELATED AMYLOIDOSIS [J].
DESTRIHOU, CV ;
JADOUL, M ;
MALGHEM, J ;
MALDAGUE, B ;
JAMART, J .
KIDNEY INTERNATIONAL, 1991, 39 (05) :1012-1019
[9]
CYTOKINES - AGENTS-PROVOCATEURS IN HEMODIALYSIS [J].
DINARELLO, CA ;
HARRINGTON, JT ;
KING, A ;
KASSIRER, JP ;
LEVEY, AS ;
MEYER, K ;
KURTIN, P ;
GELFAND, J ;
PEREIRA, BJG ;
SINGH, A .
KIDNEY INTERNATIONAL, 1992, 41 (03) :683-694
[10]
FIORENTINO DF, 1991, J IMMUNOL, V147, P3815